The European Commission has granted marketing authorisation to a treatment reducing the risk of measles in non-vaccinated patients. Privigen, developed by CSL, is a human immunoglobulin therapy indicated for pre- and post-exposure prophylaxis to prevent and reduce the risk of measles where vaccination is contraindicated or not recommended. Read More
GSK’s vaccine for the prevention of measles, mumps and rubella (MMR) has been approved by the US FDA, the company has announced. The approval of GSK’s Priorix in the US gives patients another option for being vaccinated against MMR. The vaccine is already licensed in over… Read More
While reported measles cases have fallen compared to previous years, progress toward measles elimination continues to decline and the risk of outbreaks is mounting, according to a new report from the World Health Organization (WHO) and US Centers for Disease Control and Prevention (CDC). During 2020,… Read More
